Drug Trial Radar · NCT04306315
Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight
Last checked: Nov 20, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
385
Actual
Start
Jul 21, 2022
Primary completion
Aug 25, 2025
Study completion Jan 5, 2026
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Mar 12, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study investigates if an adjusted brodalumab dosage regimen will give improved efficacy in psoriasis in patients with a body weight of over 120 kg. The increased dosage regimen will be compared to the standard brodalumab treatment plus placebo.
Conditions
- Psoriasis Vulgaris
Interventions
BrodalumabBiological
Brodalumab is an anti-IL-17 receptor antibody, which blocks the inflammatory effects of IL-17 in the skin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Having at least 90% lower Psoriasis Area and Severity Index (PASI) score relative to baseline (PASI 90 response) at Week 40.Time frame: Week 40
Locations
81 sites in 11 countries. Site status is shown where the registry gives one.
LEO Pharma Investigational Site
Brussels, Belgium
LEO Pharma Investigational Site
Ham-sur-Heure-Nalinnes, Belgium
LEO Pharma Investigational Site
Leuven, Belgium
LEO Pharma Investigational Site
Liège, Belgium
LEO Pharma Investigational Site
Kutná Hora, Czechia
LEO Pharma Investigational Site
Nový Jičín, Czechia
LEO Pharma Investigational Site
Plzen-Bory, Czechia
LEO Pharma Investigational Site
Saint-Priest-en-Jarez, France
LEO Pharma Investigational Site
Toulouse, France
LEO Pharma Investigational Site
Valence, France
LEO Pharma Investigational Site
Amiens, Somme, France
LEO Pharma Investigational Site
Bad Bentheim, Germany
LEO Pharma Investigational Site
Bielefeld, Germany
LEO Pharma Investigational Site
Hamburg, Germany
LEO Pharma Investigational Site
Memmingen, Germany
LEO Pharma Investigational Site
Münster, Germany
LEO Pharma Investigational Site
Oldenburg, Germany
LEO Pharma Investigational Site
Osnabrück, Germany
LEO Pharma Investigational Site
Langenau, Baden-Wurttemberg, Germany
LEO Pharma Investigational Site
Limburg an der Lahn, Hesse, Germany
LEO Pharma Investigational Site
Wiesbaden, Hesse, Germany
LEO Pharma Investigational Site
Lohne, Lower Saxony, Germany
LEO Pharma Investigational Site
Mainz, Rhineland-Palatinate, Germany
LEO Pharma Investigational Site
Kiel, Schleswig-Holstein, Germany
LEO Pharma Investigational Site
Berlin, State of Berlin, Germany
LEO Pharma Investigational Site
Athens, Greece
LEO Pharma Investigational Site
Athens, Greece
LEO Pharma Investigational Site
Piraeus, Greece
LEO Pharma Investigational Site
Thessaloniki, Greece
LEO Pharma Investigational Site
Thessaloniki, Greece
LEO Pharma Investigational Site
Thessaloniki, Greece
LEO Pharma Investigational Site
Heraklion, Crete, Greece
LEO Pharma Investigational Site
Debrecen, Hungary
LEO Pharma Investigational Site
Orosháza, Hungary
LEO Pharma Investigational Site
Szolnok, Hungary
LEO Pharma Investigational Site
Veszprém, Hungary
LEO Pharma Investigational Site
Ancona, Italy
LEO Pharma Investigational Site
Bologna, Italy
LEO Pharma Investigational Site
Brescia, Italy
LEO Pharma Investigational Site
Coppito, Italy
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.